Malta - English - Medicines Authority

lundbeck limited - flupentixol - film-coated tablet - flupentixol 0.5 mg - psycholeptics

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - testosterone undecanoate, quantity: 40 mg - capsule, soft - excipient ingredients: propylene glycol monolaurate; hydrogenated castor oil; medium chain triglycerides; gelatin; sunset yellow fcf; lecithin; glycerol; titanium dioxide; propylene glycol; ethyl acetate; isopropyl alcohol; purified water; ethanol; strong ammonia solution; polyvinyl acetate phthalate; macrogol 400 - androgen replacement therapy for confirmed testosterone deficiency in males, when testosterone deficiency has been confirmed by clinical features and biochemical tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

lundbeck australia pty ltd - zuclopenthixol decanoate, quantity: 200 mg - injection, solution - excipient ingredients: fractionated coconut oil - maintenance treatment of acute psychoses, mania and exacerbation of chronic psychoses. may be an advantage in the treatment of noncompliant patients.

United States - English - NLM (National Library of Medicine)

american regent, inc. - nandrolone decanoate (unii: h45187t098) (nandrolone - unii:6pg9vr430d) - nandrolone decanoate is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. surgically induced anephric patients have been reported to be less responsive. - male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. - carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. - pregnancy, because of masculinization of the fetus. - nephrosis or the nephrotic phase of nephritis. nandrolone decanoate injection is classified as a schedule iii controlled substance under the anabolic steroids control act of 1990.

United States - English - NLM (National Library of Medicine)

par pharmaceutical, inc. - fluphenazine decanoate (unii: fmu62k1l3c) (fluphenazine - unii:s79426a41z) - fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in the management of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronic schizophrenics). fluphenazine decanoate injection has not been shown effective in the management of behavioral complications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. phenothiazine compounds should not be used in patients receiving large doses of hypnotics. fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. fluphenazine decanoate injection is not intended for use in children under 12 years of age. fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.

United States - English - NLM (National Library of Medicine)

mylan institutional llc - fluphenazine decanoate (unii: fmu62k1l3c) (fluphenazine - unii:s79426a41z) - fluphenazine decanoate injection is a long-acting parenteral antipsychotic drug intended for use in themanagement of patients requiring prolonged parenteral neuroleptic therapy (e.g., chronicschizophrenics). fluphenazine decanoate injection has not been shown effective in the management of behavioralcomplications in patients with mental retardation. phenothiazines are contraindicated in patients with suspected or established subcortical brain damage. phenothiazine compounds should not be used in patients receiving large doses of hypnotics. fluphenazine decanoate injection is contraindicated in comatose or severely depressed states. the presence of blood dyscrasia or liver damage precludes the use of fluphenazine decanoate. fluphenazine decanoate injection is not intended for use in children under 12 years of age. fluphenazine decanoate injection is contraindicated in patients who have shown hypersensitivity to fluphenazine; cross-sensitivity to phenothiazine derivatives may occur.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg/ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions ). - parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection is indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies).

United States - English - NLM (National Library of Medicine)

somerset therapeutics, llc - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection, 50 mg (base)/ml and haloperidol decanoate injection, 100 mg (base)/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection, 50 mg /ml and haloperidol decanoate injection, 100 mg/ml are attributed to haloperidol, usp as the active medication, contraindications, warnings, and additional information are those of haloperidol, usp, modified only to reflect the prolonged action.   haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson's disease (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurological adverse reactions in patients with parkinson's disease or dementia with lewy bodies).

United States - English - NLM (National Library of Medicine)

teva parenteral medicines, inc. - haloperidol decanoate (unii: ac20pj4101) (haloperidol - unii:j6292f8l3d) - haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are indicated for the treatment of patients with schizophrenia who require prolonged parenteral antipsychotic therapy. since the pharmacologic and clinical actions of haloperidol decanoate injection 50 mg/ml and haloperidol decanoate injection 100 mg/ml are attributed to haloperidol as the active medication, contraindications, warnings, and additional information are those of haloperidol, modified only to reflect the prolonged action. haloperidol is contraindicated in patients with: - severe toxic central nervous system depression or comatose states from any cause. - hypersensitivity to this drug – hypersensitivity reactions have included anaphylactic reaction and angioedema (see warnings, hypersensitivity reactions and adverse reactions). - parkinson’s disease (see warnings, neurological adverse reactions in patients with parkinson’s disease or dementia with lewy bodies). - dementia with lewy bodies (see warnings, neurolog